Positive allosteric modulation of AMPA receptors via PF4778574 leads to reduced demyelination and clinical disability in experimental models of multiple sclerosis.

These observations suggest that PF4778574 may enhance remyelination, even if some marker-quantification did not reach statistical significance. 4 Discussion In the present study, we aimed to systematically investigate the therapeutic and preventive effects of the type-II AMPA-PAM PF4778574 as well as a combination therapy of PF4778574 and fingolimod, - as an example for an approved immunomodulatory treatment for MS - on EAEON, an established experimental rodent model of MS optic neuritis.

also in 111,027 other papers